LOXL2 and breast carcinoma: LOXL2, a copper-containing enzyme, is closely related to reduced survival time and poor prognosis since it promotes the proliferation, migration, invasion, and metastasis of numerous types of cancers, including breast cancer, lung cancer, colon cancer, and liver cancer.